Myovant Sciences Current Ratio 2017-2022 | MYOV
Myovant Sciences current ratio from 2017 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Myovant Sciences Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-12-31 |
$0.39B |
$0.25B |
1.57 |
| 2022-09-30 |
$0.46B |
$0.25B |
1.83 |
| 2022-06-30 |
$0.43B |
$0.23B |
1.89 |
| 2022-03-31 |
$0.49B |
$0.25B |
1.95 |
| 2021-12-31 |
$0.58B |
$0.27B |
2.14 |
| 2021-09-30 |
$0.66B |
$0.27B |
2.44 |
| 2021-06-30 |
$0.70B |
$0.31B |
2.28 |
| 2021-03-31 |
$0.71B |
$0.28B |
2.51 |
| 2020-12-31 |
$0.75B |
$0.25B |
2.99 |
| 2020-09-30 |
$0.12B |
$0.07B |
1.75 |
| 2020-06-30 |
$0.11B |
$0.05B |
2.07 |
| 2020-03-31 |
$0.09B |
$0.09B |
1.02 |
| 2019-12-31 |
$0.11B |
$0.05B |
2.08 |
| 2019-09-30 |
$0.17B |
$0.06B |
2.79 |
| 2019-06-30 |
$0.24B |
$0.07B |
3.42 |
| 2019-03-31 |
$0.17B |
$0.07B |
2.32 |
| 2018-12-31 |
$0.20B |
$0.06B |
3.51 |
| 2018-09-30 |
$0.16B |
$0.05B |
3.41 |
| 2018-06-30 |
$0.15B |
$0.05B |
3.07 |
| 2018-03-31 |
$0.12B |
$0.04B |
3.10 |
| 2017-12-31 |
$0.14B |
$0.03B |
5.04 |
| 2017-09-30 |
$0.13B |
$0.02B |
7.79 |
| 2017-06-30 |
$0.16B |
$0.02B |
9.27 |
| 2017-03-31 |
$0.18B |
$0.02B |
10.04 |
| 2016-12-31 |
$0.19B |
$0.01B |
30.53 |
| 2016-09-30 |
$0.00B |
$0.01B |
0.02 |
| 2016-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2016-03-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.614B |
$0.231B |
|
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
|
